By continuing to use this website, you agree to the Terms & Conditions and Privacy Policy.
Hemophilia A (factor VIII [factor 8] deficiency) is an X-linked inherited coagulation factor deficiency. The severity and frequency of bleeding that patients experience is variable and dependent on the degree of factor deficiency. While the management of hemophilia A has improved significantly in recent years with the availability of factor replacement agents optimal management remains complex and a clinical challenge. This activity features a multidisciplinary panel discussion of clinical trial efficacy and safety data for newer agents, and emerging strategies for the prophylactic management of patients with hemophilia A with or without inhibitors.
Hemophilia A (factor VIII [factor 8] deficiency) is an X-linked inherited coagulation factor deficiency. The severity and frequency of bleeding that patients experience is variable and dependent on the degree of factor deficiency. While the management of hemophilia A has improved significantly in recent years with the availability of factor replacement agents optimal management remains complex and a clinical challenge. This activity features a multidisciplinary panel discussion of clinical trial efficacy and safety data for newer agents, and emerging strategies for the prophylactic management of patients with hemophilia A with or without inhibitors.
By continuing to use this website, you agree to the Terms & Conditions and Privacy Policy.